View in EDS

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.

Saved in:
Bibliographic Details
Title: Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.
Authors: Sherman S; Department of Medical Oncology and., Sandusky ZM; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Russo D; Department of Medical Oncology and.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Zak D; Department of Cancer Biology, Loyola University Stritch School of Medicine, Maywood, Illinois, USA., Nardone A; Department of Medical Oncology and., Friel D; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Hermida-Prado F; Department of Medical Oncology and., Heraud C; Department of Medical Oncology and., Kuziel G; Department of Medical Oncology and., Verma A; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Gaglia G; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Kabraji S; Department of Medical Oncology and.; Harvard Medical School, Boston, Massachusetts, USA.; Susan F. Smith Center for Women's Cancers and., Nguyen QD; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Santagata S; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Fanning SW; Department of Cancer Biology, Loyola University Stritch School of Medicine, Maywood, Illinois, USA., Jeselsohn R; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Susan F. Smith Center for Women's Cancers and.
Source: JCI insight [JCI Insight] 2025 May 06; Vol. 10 (12). Date of Electronic Publication: 2025 May 06 (Print Publication: 2025).
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: eCollection Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40327396
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sherman+S%22">Sherman S</searchLink>; Department of Medical Oncology and.<br /><searchLink fieldCode="AU" term="%22Sandusky+ZM%22">Sandusky ZM</searchLink>; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Russo+D%22">Russo D</searchLink>; Department of Medical Oncology and.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Zak+D%22">Zak D</searchLink>; Department of Cancer Biology, Loyola University Stritch School of Medicine, Maywood, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Nardone+A%22">Nardone A</searchLink>; Department of Medical Oncology and.<br /><searchLink fieldCode="AU" term="%22Friel+D%22">Friel D</searchLink>; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hermida-Prado+F%22">Hermida-Prado F</searchLink>; Department of Medical Oncology and.<br /><searchLink fieldCode="AU" term="%22Heraud+C%22">Heraud C</searchLink>; Department of Medical Oncology and.<br /><searchLink fieldCode="AU" term="%22Kuziel+G%22">Kuziel G</searchLink>; Department of Medical Oncology and.<br /><searchLink fieldCode="AU" term="%22Verma+A%22">Verma A</searchLink>; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Gaglia+G%22">Gaglia G</searchLink>; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Kabraji+S%22">Kabraji S</searchLink>; Department of Medical Oncology and.; Harvard Medical School, Boston, Massachusetts, USA.; Susan F. Smith Center for Women's Cancers and.<br /><searchLink fieldCode="AU" term="%22Nguyen+QD%22">Nguyen QD</searchLink>; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Santagata+S%22">Santagata S</searchLink>; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Fanning+SW%22">Fanning SW</searchLink>; Department of Cancer Biology, Loyola University Stritch School of Medicine, Maywood, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Jeselsohn+R%22">Jeselsohn R</searchLink>; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Susan F. Smith Center for Women's Cancers and.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101676073%22">JCI insight</searchLink> [JCI Insight] 2025 May 06; Vol. 10 (12). <i>Date of Electronic Publication: </i>2025 May 06 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101676073 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2379-3708 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223793708%22">23793708 </searchLink><i>NLM ISO Abbreviation: </i>JCI Insight <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40327396
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1172/jci.insight.188051
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sherman S
      – PersonEntity:
          Name:
            NameFull: Sandusky ZM
      – PersonEntity:
          Name:
            NameFull: Russo D
      – PersonEntity:
          Name:
            NameFull: Zak D
      – PersonEntity:
          Name:
            NameFull: Nardone A
      – PersonEntity:
          Name:
            NameFull: Friel D
      – PersonEntity:
          Name:
            NameFull: Hermida-Prado F
      – PersonEntity:
          Name:
            NameFull: Heraud C
      – PersonEntity:
          Name:
            NameFull: Kuziel G
      – PersonEntity:
          Name:
            NameFull: Verma A
      – PersonEntity:
          Name:
            NameFull: Gaglia G
      – PersonEntity:
          Name:
            NameFull: Kabraji S
      – PersonEntity:
          Name:
            NameFull: Nguyen QD
      – PersonEntity:
          Name:
            NameFull: Santagata S
      – PersonEntity:
          Name:
            NameFull: Fanning SW
      – PersonEntity:
          Name:
            NameFull: Jeselsohn R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 05
              Text: 2025 May 06
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2379-3708
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: JCI insight
              Type: main
ResultId 1